are winners!

Top News

 Vancouver, Canada (October 19, 2020) - XPhyto Therapeutics Corp. (CSE:XPHY / OTC:XPHYF / FSE:4XT) (“XPhyto” or the “Company”), a next-generation bioscience company, is pleased to announce an update on its third-party contract development programs. Over the past 12 months, XPhyto’s wholly owned German subsidiary, Vektor Pharma TF GmbH (“Vektor”), has developed an oral disintegrating film (“ODF”) dosage formulation for a major European generic drug company. In Q3 2020, Vektor completed manufacturing of ODF clinical trial materials which will now be delivered for clinical ... [ more ]